A phase II Clinical study of TARA-002 in pediatric Lymphatic Malformations patients
Latest Information Update: 14 Mar 2023
At a glance
- Drugs Picibanil (Primary)
- Indications Lymphangioma
- Focus Adverse reactions; Registrational
- 08 Mar 2023 According to a Protara Therapeutics media release, trial initiation expected in 2H23
- 03 Nov 2022 According to a Protara Therapeutics media release, the company has received initial feedback from the Vaccines and Related Products Division of the FDA on the protocol for the trial and the company is in process of finalizing the trial design.
- 03 Nov 2022 According to a Protara Therapeutics media release, the company has received initial feedback from USFDA and the trial is expected to initiate in 2023.